1. Academic Validation
  2. 2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase

2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase

  • Bioorg Med Chem Lett. 2011 Nov 1;21(21):6322-7. doi: 10.1016/j.bmcl.2011.08.114.
Martin J Walsh 1 Kyle R Brimacombe Henrike Veith James M Bougie Thomas Daniel William Leister Lewis C Cantley William J Israelsen Matthew G Vander Heiden Min Shen Douglas S Auld Craig J Thomas Matthew B Boxer
Affiliations

Affiliation

  • 1 NIH Chemical Genomics Center, NIH Center for Translational Therapeutics, National Human Genome Research Institute, National Institutes of Health, 9800 Medical Center Drive, Rockville, MD 20850, USA.
Abstract

Compared to normal differentiated cells, Cancer cells have altered metabolic regulation to support biosynthesis and the expression of the M2 isozyme of Pyruvate Kinase (PKM2) plays an important role in this anabolic metabolism. While the M1 isoform is a highly active Enzyme, the alternatively spliced M2 variant is considerably less active and expressed in tumors. While the exact mechanism by which decreased Pyruvate Kinase activity contributes to anabolic metabolism remains unclear, it is hypothesized that activation of PKM2 to levels seen with PKM1 may promote a metabolic program that is not conducive to cell proliferation. Here we report the third chemotype in a series of PKM2 activators based on the 2-oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamide scaffold. The synthesis, structure activity relationships, selectivity and notable physiochemical properties are described.

Figures
Products